Elucidating the Mechanisms of Hugan Buzure Granule in the Treatment of Liver Fibrosis via Network Pharmacology

Abstract EN

Objective.

To holistically explore the latent active ingredients, targets, and related mechanisms of Hugan buzure granule (HBG) in the treatment of liver fibrosis (LF) via network pharmacology.

Methods.

First, we collected the ingredients of HBG by referring the TCMSP server and literature and filtered the active ingredients though the criteria of oral bioavailability ≥30% and drug-likeness index ≥0.18.

Second, herb-associated targets were predicted and screened based on the BATMAN-TCM and SwissTargetPrediction platforms.

Candidate targets related to LF were collected from the GeneCards and OMIM databases.

Furthermore, the overlapping target genes were used to construct the protein-protein interaction network and “drug-compound-target-disease” network.

Third, GO and KEGG pathway analyses were carried out to illustrate the latent mechanisms of HBG in the treatment of LF.

Finally, the combining activities of hub targets with active ingredients were further verified based on software AutoDock Vina.

Results.

A total of 25 active ingredients and 115 overlapping target genes of HBG and LF were collected.

Besides, GO enrichment analysis exhibited that the overlapping target genes were involved in DNA-binding transcription activator activity, RNA polymerase II-specific, and oxidoreductase activity.

Simultaneously, the key molecular mechanisms of HBG against LF were mainly involved in PI3K-AKT, MAPK, HIF-1, and NF-κB signaling pathways.

Also, molecular docking simulation demonstrated that the key targets of HBG for antiliver fibrosis were IL6, CASP3, EGFR, VEGF, and MAPK.

Conclusion.

This work validated and predicted the underlying mechanisms of multicomponent and multitarget about HBG in treating LF and provided a scientific foundation for further research.